SCHEMBL19973415

SCHEMBL19973415

CNC(=O)NC1CCOc2c(C(=O)Nc3ccc(F)c(F)c3)ccc(Cl)c21

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.43
RAB9A P51151 7/20 0.43
ENPP2 Q13822 1/20 0.43
MAOB P27338 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
KMT2A Q03164 1/20 0.39
MAPT P10636 1/20 0.39
PYGL P06737 1/20 0.38
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
NTRK1 P04629 1/20 0.38
EPHX2 P34913 1/20 0.38
MET P08581 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19973414 1.00 NPC1 (0.43) NPC1RAB9AENPP2MAOBSMN1; SMN2
SCHEMBL19973906 0.92 MAOB (0.42) NPC1RAB9AENPP2MAOBSMN1; SMN2
SCHEMBL21175569 0.92 MAOB (0.42) NPC1RAB9AENPP2MAOBSMN1; SMN2
SCHEMBL19973905 0.92 MAOB (0.42) NPC1RAB9AENPP2MAOBSMN1; SMN2
SCHEMBL19973490 0.90 KMT2A (0.47) NPC1RAB9ASMN1; SMN2MEN1ALDH1A1
SCHEMBL19973489 0.90 KMT2A (0.47) NPC1RAB9ASMN1; SMN2MEN1ALDH1A1
SCHEMBL19973475 0.89 NPC1 (0.45) NPC1RAB9AENPP2MAOBSMN1; SMN2
SCHEMBL19973474 0.89 NPC1 (0.45) NPC1RAB9AENPP2MAOBSMN1; SMN2
SCHEMBL21189409 0.89 NPC1 (0.43) NPC1RAB9AENPP2MAOBSMN1; SMN2
SCHEMBL19973980 0.85 HTR2B (0.39) NPC1RAB9ASMN1; SMN2MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2021-05-11 US claimed
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2019-07-25 US claimed
WO-2018052967-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA, INC. (US) 2018-03-22 WO claimed
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2021-05-11 US disclosed
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2019-07-25 US disclosed
WO-2018052967-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA, INC. (US) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME CBX8, HAVCR2, HCCS NPC1 983/4885RAB9A 1393/4885ENPP2 3131/4885
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same CBX8, HAVCR2, HCCS NPC1 983/4885RAB9A 1393/4885ENPP2 3131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.